Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer

JCO Oncology Practice Podcast
04/03/2017 13 min
Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer

Listen "Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr. David Jackman of Dana-Farber Cancer Institute discusses how after introduction of a clinical pathway in metastatic NSCLC, cost of care decreased significantly with no compromise in survival.

More episodes of the podcast JCO Oncology Practice Podcast

A Podcast About Podcasts: Podcasts as Educational Tools for Providers (and Patients) 21/10/2025
Advance Care Planning: How Can We Improve Access and Uptake? 20/10/2025
2025 ASCO Quality: Creating a Statewide Cancer Drug Repository Network to Improve Access and Affordability 11/10/2025
"Mainstreaming" Germline Genetic Testing: How Nongenetics Providers Can Help Fill the Workforce Gap 15/09/2025
Promoting Resilience in Adolescents and Young Adults (AYAs) with Cancer via Developmentally Targeted, Evidence-Based Interventions 18/08/2025
Incomplete Reporting and Toxicity-Minimizing Language in Oncology 21/07/2025
Park the Parking: Patient and Caregiver Perspectives on Transportation Barriers in Cancer 16/06/2025
Pregnancy and Breast Cancer 19/05/2025
Treatment De-escalation for Favorable Risk Breast Cancer 21/04/2025
Prior Authorization: How Did We Get Here and Where Are We Going? 17/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA